The prevalence of type 2 diabetes (T2DM) is increasing sharply around the world and obesity and sedentary lifestyles are driving the epidemic. Obesity is often, but not always present in patients with T2DM. The primary aim of this study is to understand the impact of the ratio of lean body mass (metabolically active skeletal muscle) to adipose tissue mass on the severity of insulin resistance and pancreatic beta cell dysfunction in non-obese and obese Qatar residents with T2DM. An exercise programme aimed to increase lean mass and aerobic capacity will be initiated for a period 10 weeks in non-obese and obese early onset diabetics who are residents of Qatar. The effect of the exercise programme on total body fat, regional fat distribution and intramuscular and intrahepatic fat content using magnetic resonance imaging (MRI) in these groups of diabetics will be assessed and related to total body insulin sensitivity and β-cell function as measured with the gold standard methods: the euglycemic clamp technique and arginine stimulation. Genetic approaches including candidate gene testing and non-targeted miRNA expression profiling and metabolomics are employed. Physical fitness pre- and post-intervention will also be assessed. The impact of the exercise programme on conventional inflammatory markers, the phenotype of immune cells, metabolic hormones, and markers of oxidative stress, endoplasmic reticulum stress and heat shock response (Hsp-72, Hsp -40/DNAJB3 and Hsp-25) are studied in relation to metabolic changes. Through this study, the contributions of fitness, fatness and exercise training on insulin resistance and beta cell function will be elucidated in Qatari residents with T2DM.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
Hamad Medical Corporation
Doha, Qatar
RECRUITINGInsulin sensitivity
Insulin sensitivity will be assessed using a modification of the De Fronzo technique 2-hour Euglycemic Clamp procedure.
Time frame: 10 weeks
Glucose regulation/ insulin sensitivity
Glucose regulation and insulin sensitivity will be assessed via a 4-hour Oral glucose tolerance test procedure.
Time frame: 10 weeks
Pancreatic beta-cell function
Pancreatic beta-cell function will be assessed using a 3-hour Arginine stimulation test procedure.
Time frame: 10 weeks
Hepatic insulin resistance index
The measurement of hepatic insulin resistance index will completed during euglycemic clamp procedure.
Time frame: 10 weeks
Vascular reactivity
Endothelial reactivity will be assessed during the euglycemic clamp procedure, using an standard blood pressure arm cuff and the VENDYS instrument.
Time frame: 10 weeks
Body Mass Index (BMI)
Patient's weight and height will be measured in kilograms (kg) and meters (m), respectively, and combined to report BMI in kg/m\^2
Time frame: 10 weeks
Body fat profiling
Mesenteric, hepatic, subcutaneous and skeletal muscle infiltrating fat will be measured with a 3.0T MR-scanner using a whole-body Dixon protocol. Hepatic fat content and skeletal muscle fat infiltration will be measured. All measurements will be performed with 3T Phillips Ingenia scanner.
Time frame: 10 weeks
Total body fat
Dual energy X-ray absorptiometry (DEXA), via the Lunar iDXA instrument and enCORE software will be used to derive total body fat.
Time frame: 10 weeks
Non-fat mass
Dual energy X-ray absorptiometry (DEXA), via the Lunar iDXA instrument and enCORE software will be used to derive non-fat mass.
Time frame: 10 weeks
Visceral adipose volume
Dual energy X-ray absorptiometry (DEXA), via the Lunar iDXA instrument and enCORE software will be used to derive estimates of visceral adipose volume.
Time frame: 10 weeks
Cardiorespiratory fitness (estimated maximal oxygen uptake)
Maximal oxygen uptake (VO2max) will be estimated using the Astrand and Rhyming cycle ergometer protocol.
Time frame: 10 weeks
Upper body strength
Upper body strength will be determined via handgrip strength using a handgrip dynanmometer. Assessments will be conducted on both hands.
Time frame: 10 weeks
Physical function
Physical function will be measured using the 6-minute walk test.
Time frame: 10 weeks
Lower body strength
Lower body strength will be assessed using the 30-s sit to stand test.
Time frame: 10 weeks
Fasting Plasma glucose
The number of particiapnts that have improvement in fasting plasma glucose.
Time frame: 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.